David E Parry, MD in Pocatello, ID - Medicare Allergy/immunology

David E Parry, MD is a medicare enrolled "Allergy & Immunology - Allergy" physician in Pocatello, Idaho. He went to University Of Wisconsin School Of Medicine and graduated in 1992 and has 32 years of diverse experience with area of expertise as Allergy/immunology. His current practice location is 500 S 11th Ave, Suite 202, Pocatello, Idaho. You can reach out to his office (for appointments etc.) via phone at (208) 233-0801.

David E Parry is licensed to practice in Idaho (license number M7334) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1295769594.

Contact Information

	David E Parry, MD
	500 S 11th Ave, Suite 202, Pocatello, ID 83201-4835
	(208) 233-0801
	(208) 233-0803

Physician's Profile

Full Name	David E Parry
Gender	Male
Speciality	Allergy/immunology
Experience	32 Years
Location	500 S 11th Ave, Pocatello, Idaho
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

David E Parry attended and graduated from University Of Wisconsin School Of Medicine in 1992

NPI Data:

NPI Number: 1295769594
Provider Enumeration Date: 07/10/2006
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID: 8921135971
Enrollment ID: I20100422000563

Medical Identifiers

Medical identifiers for David E Parry such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1295769594	NPI	-	NPPES
M7334	Other	ID	STATE LICENSE
804258400	Medicaid	ID
040011016	Other	ID	RR MEDICARE
DI361	Other	ID	BLUE CROSS OF ID
000010003882	Other	ID	BLUE SHIELD OF ID

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207KA0200X	Allergy & Immunology - Allergy	M7334 (Idaho)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Portneuf Medical Center	Pocatello, ID	Hospital

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. David E Parry is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
David E Parry, MD 500 S 11th Ave, Suite 202, Pocatello, ID 83201 Ph: (208) 233-0801	David E Parry, MD 500 S 11th Ave, Suite 202, Pocatello, ID 83201-4835 Ph: (208) 233-0801

News Archive

NSU offers free dental services to victims of domestic violence

Nova Southeastern University (NSU) is offering free dental services to victims of domestic violence, who otherwise may not have access to such services.

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

PRI's 'The World' examines role of churches in fight against HIV in Swaziland

PRI's "The World" examines the role of churches in the fight against HIV in Swaziland. The news service highlights several church-run HIV programs, writing, "Churches have long played an important role in caring for the sick, but in terms of HIV prevention they've been at odds with the public health community. It has often come down to one issue: until recently, Swazi church leaders publicly rejected the use of condoms by their congregants. But now you hear many comments that suggest a change in thinking."

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

David E Parry, MD - Medicare Allergy/immunology in Pocatello, ID